
                                SEQUENCE LISTING

<110> Fred Hutchinson Cancer Research Center
      Riddell, Stanley R.
      Liu, Lingfeng

<120> TAGGED CHIMERIC EFFECTOR MOLECULES AND
  RECEPTORS THEREOF

<130> 360056.426WO

<140> PCT                 
<141> 2014-12-22  

<150> US 61/919,201                  
<151> 2013-12-20

<160> 73

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> Strep-tag II

<400> 1
Trp Ser His Pro Gln Phe Glu Lys
 1               5

<210> 2
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> Strep-tag

<400> 2
Trp Arg His Pro Gln Phe Gly Gly
 1               5

<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> Flag Tag

<400> 3
Asp Tyr Lys Asp Asp Asp Asp Lys
 1               5

<210> 4
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> Xpress tag

<400> 4
Asp Leu Tyr Asp Asp Asp Asp Lys
 1               5

<210> 5
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> Avi tag

<400> 5
Gly Leu Asn Asp Ile Phe Glu Ala Gln Lys Ile Glu Trp His Glu
 1               5                  10                  15

<210> 6
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> HA tag

<400> 6
Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
 1               5

<210> 7
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> Myc tag

<400> 7
Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu
 1               5                  10

<210> 8
<211> 14
<212> PRT
<213> Artificial Sequence

<220> 
<223> V5 tag

<400> 8
Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr
 1               5                  10

<210> 9
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> Soft tag 1

<400> 9
Ser Leu Ala Glu Leu Leu Asn Ala Gly Leu Gly Gly Ser
 1               5                  10

<210> 10
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker

<400> 10
Gly Gly Gly Gly Ser
 1               5

<210> 11
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker

<400> 11
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1               5                  10

<210> 12
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker

<400> 12
Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Ser
 1               5                  10

<210> 13
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker

<400> 13
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1               5                  10                  15

<210> 14
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker

<400> 14
Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
 1               5                  10                  15

<210> 15
<211> 12
<212> PRT
<213> Artificial Sequence

<220> 
<223> IgG4 Hinge

<400> 15
Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro
 1               5                  10

<210> 16
<211> 28
<212> PRT
<213> Artificial Sequence

<220> 
<223> CD28 transmembrane domain

<400> 16
Met Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser
 1               5                  10                  15
Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val
            20                  25

<210> 17
<211> 42
<212> PRT
<213> Artificial Sequence

<220> 
<223> 4 1BB portion

<400> 17
Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met
 1               5                  10                  15
Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe
            20                  25                  30
Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu
        35                  40

<210> 18
<211> 112
<212> PRT
<213> Artificial Sequence

<220> 
<223> CD3 zeta  portion

<400> 18
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
 1               5                  10                  15
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
            20                  25                  30
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
        35                  40                  45
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
    50                  55                  60
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
65                  70                  75                  80
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
                85                  90                  95
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
            100                 105                 110

<210> 19
<211> 26
<212> PRT
<213> Artificial Sequence

<220> 
<223> Calmodulin tag

<400> 19
Lys Arg Arg Trp Lys Lys Asn Phe Ile Ala Val Ser Ala Ala Asn Arg
 1               5                  10                  15
Phe Lys Lys Ile Ser Ser Ser Gly Ala Leu
            20                  25

<210> 20
<211> 18
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker+tag

<400> 20
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Trp Ser His Pro Gln Phe
 1               5                  10                  15
Glu Lys


<210> 21
<211> 18
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker+tag

<400> 21
Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Gly Ser Gly Gly Gly
 1               5                  10                  15
Gly Ser


<210> 22
<211> 37
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker tag 
      

<400> 22
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Trp Ser His Pro Gln Phe
 1               5                  10                  15
Glu Lys Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Ser Trp Ser His
            20                  25                  30
Pro Gln Phe Glu Lys
        35

<210> 23
<211> 37
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker tag 
      

<400> 23
Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Ser Gly Gly Gly Ser
 1               5                  10                  15
Gly Gly Ser Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Gly Ser
            20                  25                  30
Gly Gly Gly Gly Ser
        35

<210> 24
<211> 55
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker tag 
      

<400> 24
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Trp Ser His Pro Gln Phe
 1               5                  10                  15
Glu Lys Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Ser Trp Ser His
            20                  25                  30
Pro Gln Phe Glu Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Trp
        35                  40                  45
Ser His Pro Gln Phe Glu Lys
    50                  55

<210> 25
<211> 55
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker tag 
      

<400> 25
Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Gly Ser Gly Gly Gly
 1               5                  10                  15
Gly Ser Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Ser Gly Gly
            20                  25                  30
Gly Ser Gly Gly Ser Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly
        35                  40                  45
Gly Ser Gly Gly Gly Gly Ser
    50                  55

<210> 26
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> core hinge region
      

<400> 26
Cys Pro Pro Cys Pro
 1               5

<210> 27
<211> 36
<212> DNA
<213> Artificial Sequence

<220> 
<223> IgG4 Hinge 
      

<400> 27
gagagcaagt acggaccgcc ctgcccccct tgccct                                36

<210> 28
<211> 84
<212> DNA
<213> Artificial Sequence

<220> 
<223> CD28 transmembrane domain

<400> 28
atgttctggg tgctggtggt ggtcggaggc gtgctggcct gctacagcct gctggtcacc      60
gtggccttca tcatcttttg ggtg                                             84

<210> 29
<211> 126
<212> DNA
<213> Artificial Sequence

<220> 
<223> 4 1BB portion

<400> 29
aaacggggca gaaagaaact cctgtatata ttcaaacaac catttatgag accagtacaa      60
actactcaag aggaagatgg ctgtagctgc cgatttccag aagaagaaga aggaggatgt     120
gaactg                                                                126

<210> 30
<211> 336
<212> DNA
<213> Artificial Sequence

<220> 
<223> CD3 zeta  portion

<400> 30
cgggtgaagt tcagcagaag cgccgacgcc cctgcctacc agcagggcca gaatcagctg      60
tacaacgagc tgaacctggg cagaagggaa gagtacgacg tcctggataa gcggagaggc     120
cgggaccctg agatgggcgg caagcctcgg cggaagaacc cccaggaagg cctgtataac     180
gaactgcaga aagacaagat ggccgaggcc tacagcgaga tcggcatgaa gggcgagcgg     240
aggcggggca agggccacga cggcctgtat cagggcctgt ccaccgccac caaggatacc     300
tacgacgccc tgcacatgca ggccctgccc ccaagg                               336

<210> 31
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> S tag 
      

<400> 31
Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln His Met Asp Ser
 1               5                  10                  15

<210> 32
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> Softag 3 
      
      

<400> 32
Thr Gln Asp Pro Ser Arg Val Gly
 1               5

<210> 33
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Engineered tag of a minimal chelation site
      
      

<400> 33
His Gly Gly His His Gly
 1               5

<210> 34
<211> 123
<212> DNA
<213> Artificial Sequence

<220> 
<223> CD28 effector domain
      
      

<400> 34
cggagcaagc ggagcagagg cggccacagc gactacatga acatgacccc cagacggcct      60
ggccccaccc ggaagcacta ccagccctac gccccaccca gggactttgc cgcctacaga     120
agc                                                                   123

<210> 35
<211> 41
<212> PRT
<213> Artificial Sequence

<220> 
<223> CD28 effector domain
      
      

<400> 35
Arg Ser Lys Arg Ser Arg Gly Gly His Ser Asp Tyr Met Asn Met Thr
 1               5                  10                  15
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
            20                  25                  30
Pro Arg Asp Phe Ala Ala Tyr Arg Ser
        35                  40

<210> 36
<211> 735
<212> DNA
<213> Artificial Sequence

<220> 
<223> anti-CD19 scFv (VH-VL) from FMC63
      
      

<400> 36
gacatccaga tgacccagac cacctccagc ctgagcgcca gcctgggcga ccgggtgacc      60
atcagctgcc gggccagcca ggacatcagc aagtacctga actggtatca gcagaagccc     120
gacggcaccg tcaagctgct gatctaccac accagccggc tgcacagcgg cgtgcccagc     180
cggtttagcg gcagcggctc cggcaccgac tacagcctga ccatctccaa cctggaacag     240
gaagatatcg ccacctactt ttgccagcag ggcaacacac tgccctacac ctttggcggc     300
ggaacaaagc tggaaatcac cggcagcacc tccggcagcg gcaagcctgg cagcggcgag     360
ggcagcacca agggcgaggt gaagctgcag gaaagcggcc ctggcctggt ggcccccagc     420
cagagcctga gcgtgacctg caccgtgagc ggcgtgagcc tgcccgacta cggcgtgagc     480
tggatccggc agccccccag gaagggcctg gaatggctgg gcgtgatctg gggcagcgag     540
accacctact acaacagcgc cctgaagagc cggctgacca tcatcaagga caacagcaag     600
agccaggtgt tcctgaagat gaacagcctg cagaccgacg acaccgccat ctactactgc     660
gccaagcact actactacgg cggcagctac gccatggact actggggcca gggcaccagc     720
gtgaccgtga gcagc                                                      735

<210> 37
<211> 245
<212> PRT
<213> Artificial Sequence

<220> 
<223> anti-CD19 scFv (VH-VL) from FMC63
      
      

<400> 37
Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly
 1               5                  10                  15
Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr
            20                  25                  30
Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
        35                  40                  45
Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60
Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
65                  70                  75                  80
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr
                85                  90                  95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr Gly Ser Thr Ser Gly
            100                 105                 110
Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val Lys
        115                 120                 125
Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser
    130                 135                 140
Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser
145                 150                 155                 160
Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly Val Ile
                165                 170                 175
Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu
            180                 185                 190
Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn
        195                 200                 205
Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys His Tyr
    210                 215                 220
Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser
225                 230                 235                 240
Val Thr Val Ser Ser
                245

<210> 38
<211> 24
<212> DNA
<213> Artificial Sequence

<220> 
<223> Strep-tag II 
      
      

<400> 38
tggagccacc cgcagttcga aaaa                                             24

<210> 39
<211> 15
<212> DNA
<213> Artificial Sequence

<220> 
<223> G4S 
      
      

<400> 39
ggaggtggag gttca                                                       15

<210> 40
<211> 15
<212> DNA
<213> Artificial Sequence

<220> 
<223> G4S 
      
      
<400> 40
ggtggtggag gctct                                                       15

<210> 41
<211> 15
<212> DNA
<213> Artificial Sequence

<220> 
<223> G4S 
     
      

<400> 41
ggtggcggag gctct                                                       15

<210> 42
<211> 30
<212> DNA
<213> Artificial Sequence

<220> 
<223> (G4S)2 
      
      

<400> 42
ggaggtggag gttcaggtgg tggaggttca                                       30

<210> 43
<211> 33
<212> DNA
<213> Artificial Sequence

<220> 
<223> G3SG3SG2S 
      
      

<400> 43
ggaggcggtt ctggaggtgg aagcggtggc tct                                   33

<210> 44
<211> 18
<212> PRT
<213> Artificial Sequence

<220> 
<223> variable domain linker 
      
      

<400> 44
Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
 1               5                  10                  15
Lys Gly


<210> 45
<211> 20
<212> PRT
<213> Artificial Sequence

<220> 
<223> variable domain linker + imbedded tag
      
<220>
<221> VARIANT        
<222> (1)...(20)
<223> Xaa = Any Amino Acid

<400> 45
Gly Gly Ser Gly Ser Gly Xaa Trp Ser His Pro Gln Phe Glu Lys Gly
 1               5                  10                  15
Ser Gly Ser Gly
            20

<210> 46
<211> 18
<212> PRT
<213> Artificial Sequence

<220> 
<223> N-terminal tag + linker

<400> 46
Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Gly Ser Gly Gly Gly
 1               5                  10                  15
Gly Ser


<210> 47
<211> 22
<212> PRT
<213> Artificial Sequence

<220> 
<223> secretory signal peptide

<400> 47
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
 1               5                  10                  15
Ala Phe Leu Leu Ile Pro
            20

<210> 48
<211> 23
<212> PRT
<213> Artificial Sequence

<220> 
<223> secretory signal peptide

<220>
<221> VARIANT        
<222> (1)...(23)
<223> Xaa = Any Amino Acid

<400> 48
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
 1               5                  10                  15
Ala Phe Leu Leu Ile Pro Xaa
            20

<210> 49
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> C-terminal junction amino acids

<400> 49
Glu Ser Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1               5                  10

<210> 50
<211> 4
<212> PRT
<213> Artificial Sequence

<220> 
<223> C-terminal junction amino acids

<400> 50
Gly Glu Ser Lys
 1

<210> 51
<211> 107
<212> PRT
<213> Artificial Sequence

<220> 
<223> anti-CD19 VH domain

<400> 51
Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly
 1               5                  10                  15
Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr
            20                  25                  30
Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
        35                  40                  45
Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60
Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
65                  70                  75                  80
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr
                85                  90                  95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr
            100                 105

<210> 52
<211> 120
<212> PRT
<213> Artificial Sequence

<220> 
<223> anti-CD19 VL domain

<400> 52
Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
 1               5                  10                  15
Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr
            20                  25                  30
Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu
        35                  40                  45
Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys
    50                  55                  60
Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu
65                  70                  75                  80
Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
                85                  90                  95
Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln
            100                 105                 110
Gly Thr Ser Val Thr Val Ser Ser
        115                 120

<210> 53
<211> 263
<212> PRT
<213> Artificial Sequence

<220> 
<223> anti-CD19 scFv (Tag-VH-VL)

<400> 53
Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Gly Ser Gly Gly Gly
 1               5                  10                  15
Gly Ser Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser
            20                  25                  30
Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser
        35                  40                  45
Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu
    50                  55                  60
Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe
65                  70                  75                  80
Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu
                85                  90                  95
Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu
            100                 105                 110
Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr Gly Ser Thr
        115                 120                 125
Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu
    130                 135                 140
Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser
145                 150                 155                 160
Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly
                165                 170                 175
Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly
            180                 185                 190
Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser
        195                 200                 205
Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys
    210                 215                 220
Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys
225                 230                 235                 240
His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly
                245                 250                 255
Thr Ser Val Thr Val Ser Ser
            260

<210> 54
<211> 247
<212> PRT
<213> Artificial Sequence

<220> 
<223> anti-CD19 scFv (VH-Tag-VL)

<400> 54
Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly
 1               5                  10                  15
Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr
            20                  25                  30
Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
        35                  40                  45
Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60
Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
65                  70                  75                  80
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr
                85                  90                  95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr Gly Gly Ser Gly Ser
            100                 105                 110
Gly Asn Trp Ser His Pro Gln Phe Glu Lys Gly Ser Gly Ser Gly Glu
        115                 120                 125
Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser
    130                 135                 140
Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly
145                 150                 155                 160
Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly
                165                 170                 175
Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser
            180                 185                 190
Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys
        195                 200                 205
Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys
    210                 215                 220
His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly
225                 230                 235                 240
Thr Ser Val Thr Val Ser Ser
                245

<210> 55
<211> 121
<212> PRT
<213> Artificial Sequence

<220> 
<223> anti-ROR1 R12 VH domain

<400> 55
Gln Glu Gln Leu Val Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Gly
 1               5                  10                  15
Ser Leu Thr Leu Ser Cys Lys Ala Ser Gly Phe Asp Phe Ser Ala Tyr
            20                  25                  30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45
Ala Thr Ile Tyr Pro Ser Ser Gly Lys Thr Tyr Tyr Ala Thr Trp Val
    50                  55                  60
Asn Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Gln Asn Thr Val Asp
65                  70                  75                  80
Leu Gln Met Asn Ser Leu Thr Ala Ala Asp Arg Ala Thr Tyr Phe Cys
                85                  90                  95
Ala Arg Asp Ser Tyr Ala Asp Asp Gly Ala Leu Phe Asn Ile Trp Gly
            100                 105                 110
Pro Gly Thr Leu Val Thr Ile Ser Ser
        115                 120

<210> 56
<211> 111
<212> PRT
<213> Artificial Sequence

<220> 
<223> anti-ROR1 R12 VL domain

<400> 56
Glu Leu Val Leu Thr Gln Ser Pro Ser Val Ser Ala Ala Leu Gly Ser
 1               5                  10                  15
Pro Ala Lys Ile Thr Cys Thr Leu Ser Ser Ala His Lys Thr Asp Thr
            20                  25                  30
Ile Asp Trp Tyr Gln Gln Leu Gln Gly Glu Ala Pro Arg Tyr Leu Met
        35                  40                  45
Gln Val Gln Ser Asp Gly Ser Tyr Thr Lys Arg Pro Gly Val Pro Asp
    50                  55                  60
Arg Phe Ser Gly Ser Ser Ser Gly Ala Asp Arg Tyr Leu Ile Ile Pro
65                  70                  75                  80
Ser Val Gln Ala Asp Asp Glu Ala Asp Tyr Tyr Cys Gly Ala Asp Tyr
                85                  90                  95
Ile Gly Gly Tyr Val Phe Gly Gly Gly Thr Gln Leu Thr Val Thr
            100                 105                 110

<210> 57
<211> 247
<212> PRT
<213> Artificial Sequence

<220> 
<223> anti-ROR1 scFv (VH-VL) from R12

<400> 57
Gln Glu Gln Leu Val Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Gly
 1               5                  10                  15
Ser Leu Thr Leu Ser Cys Lys Ala Ser Gly Phe Asp Phe Ser Ala Tyr
            20                  25                  30
Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45
Ala Thr Ile Tyr Pro Ser Ser Gly Lys Thr Tyr Tyr Ala Thr Trp Val
    50                  55                  60
Asn Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Gln Asn Thr Val Asp
65                  70                  75                  80
Leu Gln Met Asn Ser Leu Thr Ala Ala Asp Arg Ala Thr Tyr Phe Cys
                85                  90                  95
Ala Arg Asp Ser Tyr Ala Asp Asp Gly Ala Leu Phe Asn Ile Trp Gly
            100                 105                 110
Pro Gly Thr Leu Val Thr Ile Ser Ser Gly Gly Gly Gly Ser Gly Gly
        115                 120                 125
Gly Gly Ser Gly Gly Gly Gly Ser Glu Leu Val Leu Thr Gln Ser Pro
    130                 135                 140
Ser Val Ser Ala Ala Leu Gly Ser Pro Ala Lys Ile Thr Cys Thr Leu
145                 150                 155                 160
Ser Ser Ala His Lys Thr Asp Thr Ile Asp Trp Tyr Gln Gln Leu Gln
                165                 170                 175
Gly Glu Ala Pro Arg Tyr Leu Met Gln Val Gln Ser Asp Gly Ser Tyr
            180                 185                 190
Thr Lys Arg Pro Gly Val Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly
        195                 200                 205
Ala Asp Arg Tyr Leu Ile Ile Pro Ser Val Gln Ala Asp Asp Glu Ala
    210                 215                 220
Asp Tyr Tyr Cys Gly Ala Asp Tyr Ile Gly Gly Tyr Val Phe Gly Gly
225                 230                 235                 240
Gly Thr Gln Leu Thr Val Thr
                245

<210> 58
<211> 858
<212> DNA
<213> Artificial Sequence

<220> 
<223> secretory signal peptide-[anti-CD19 scFv
      (Tag-VH-VL)]

<400> 58
atgctgctgc tggtgaccag cctgctgctg tgcgagctgc cccaccccgc ctttctgctg      60
atccccaatt ggagccaccc gcagttcgaa aaaggaggtg gaggttcagg tggtggaggc     120
tctgacatcc agatgaccca gaccacctcc agcctgagcg ccagcctggg cgaccgggtg     180
accatcagct gccgggccag ccaggacatc agcaagtacc tgaactggta tcagcagaag     240
cccgacggca ccgtcaagct gctgatctac cacaccagcc ggctgcacag cggcgtgccc     300
agccggttta gcggcagcgg ctccggcacc gactacagcc tgaccatctc caacctggaa     360
caggaagata tcgccaccta cttttgccag cagggcaaca cactgcccta cacctttggc     420
ggcggaacaa agctggaaat caccggcagc acctccggca gcggcaagcc tggcagcggc     480
gagggcagca ccaagggcga ggtgaagctg caggaaagcg gccctggcct ggtggccccc     540
agccagagcc tgagcgtgac ctgcaccgtg agcggcgtga gcctgcccga ctacggcgtg     600
agctggatca ggcagccccc caggaagggc ctggaatggc tgggcgtgat ctggggcagc     660
gagaccacct actacaacag cgccctgaag agccggctga ccatcatcaa ggacaacagc     720
aagagccagg tgttcctgaa gatgaacagc ctgcagaccg acgacaccgc catctactac     780
tgcgccaagc actactacta cggcggcagc tacgccatgg actactgggg ccagggcacc     840
agcgtgaccg tgagcagc                                                   858

<210> 59
<211> 807
<212> DNA
<213> Artificial Sequence

<220> 
<223> secretory signal peptide-[anti-CD19 scFv
      (VH-Tag-VL)]

<400> 59
atgctgctgc tggtgaccag cctgctgctg tgcgagctgc cccaccccgc ctttctgctg      60
atccccgaca tccagatgac ccagaccacc tccagcctga gcgccagcct gggcgaccgg     120
gtgaccatca gctgccgggc cagccaggac atcagcaagt acctgaactg gtatcagcag     180
aagcccgacg gcaccgtcaa gctgctgatc taccacacca gccggctgca cagcggcgtg     240
cccagccggt ttagcggcag cggctccggc accgactaca gcctgaccat ctccaacctg     300
gaacaggaag atatcgccac ctacttttgc cagcagggca acacactgcc ctacaccttt     360
ggcggcggaa caaagctgga aatcaccgga ggttcaggat ctggcaattg gagccacccg     420
cagttcgaaa aaggctctgg atcaggtgag gtgaagctgc aggaaagcgg ccctggcctg     480
gtggccccca gccagagcct gagcgtgacc tgcaccgtga gcggcgtgag cctgcccgac     540
tacggcgtga gctggatcag gcagcccccc aggaagggcc tggaatggct gggcgtgatc     600
tggggcagcg agaccaccta ctacaacagc gccctgaaga gccggctgac catcatcaag     660
gacaacagca agagccaggt gttcctgaag atgaacagcc tgcagaccga cgacaccgcc     720
atctactact gcgccaagca ctactactac ggcggcagct acgccatgga ctactggggc     780
cagggcacca gcgtgaccgt gagcagc                                         807

<210> 60
<211> 807
<212> DNA
<213> Artificial Sequence

<220> 
<223> secretory signal peptide-anti-ROR1 scFv (VH-VL)

<400> 60
atgctgctgc tggtgacaag cctgctgctg tgcgagctgc cccaccccgc ctttctgctg      60
atcccccagg aacagctcgt cgaaagcggc ggcagactgg tgacacctgg cggcagcctg     120
accctgagct gcaaggccag cggcttcgac ttcagcgcct actacatgag ctgggtccgc     180
caggcccctg gcaagggact ggaatggatc gccaccatct accccagcag cggcaagacc     240
tactacgcca cctgggtgaa cggacggttc accatctcca gcgacaacgc ccagaacacc     300
gtggacctgc agatgaacag cctgacagcc gccgaccggg ccacctactt ttgcgccaga     360
gacagctacg ccgacgacgg cgccctgttc aacatctggg gccctggcac cctggtgaca     420
atctctagcg gcggaggcgg atctggtggc ggaggaagtg gcggcggagg atctgagctg     480
gtgctgaccc agagcccctc tgtgtctgct gccctgggaa gccctgccaa gatcacctgt     540
accctgagca gcgcccacaa gaccgacacc atcgactggt atcagcagct gcagggcgag     600
gcccccagat acctgatgca ggtgcagagc gacggcagct acaccaagag gccaggcgtg     660
cccgaccggt tcagcggatc tagctctggc gccgaccgct acctgatcat ccccagcgtg     720
caggccgatg acgaggccga ttactactgt ggcgccgact acatcggcgg ctacgtgttc     780
ggcggaggca cccagctgac cgtgacc                                         807

<210> 61
<211> 30
<212> DNA
<213> Artificial Sequence

<220> 
<223> (G4S)2 

<400> 61
ggaggtggag gttcaggtgg tggaggctct                                       30

<210> 62
<211> 45
<212> DNA
<213> Artificial Sequence

<220> 
<223> (G4S)3 

<400> 62
ggcggaggcg gatctggtgg cggaggaagt ggcggcggag gatct                      45

<210> 63
<211> 66
<212> DNA
<213> Artificial Sequence

<220> 
<223> secretory signal peptide

<400> 63
atgctgctgc tggtgaccag cctgctgctg tgcgagctgc cccaccccgc ctttctgctg      60
atcccc                                                                 66

<210> 64
<211> 66
<212> DNA
<213> Artificial Sequence

<220> 
<223> secretory signal peptide

<400> 64
atgctgctgc tggtgacaag cctgctgctg tgcgagctgc cccaccccgc ctttctgctg      60
atcccc                                                                 66

<210> 65
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker 
      

<400> 65
Gly Gly Ser Gly Ser Gly
 1               5

<210> 66
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker 
      

<400> 66
Gly Ser Gly Ser Gly
 1               5

<210> 67
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker 
      

<400> 67
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1               5                   10

<210> 68
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker 
      

<400> 68
Gly Gly Gly Ser Gly Gly Gly Ser
 1               5

<210> 69
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker 
      

<400> 69
Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Ser
 1               5                  10

<210> 70
<211> 28
<212> PRT
<213> Artificial Sequence

<220> 
<223> modified CD28 transmembrane domain

<400> 70
Met Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser
 1               5                  10                  15
Gly Gly Val Thr Val Ala Phe Ile Ile Phe Trp Val
            20                  25

<210> 71
<211> 4
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker 
      

<400> 71
Gly Gly Gly Ser
 1

<210> 72
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker 
      

<400> 72
Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1               5

<210> 73
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> linker 
      

<400> 73
Gly Gly Gly Ser Gly Gly Ser
 1               5
